[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100223376":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":57,"collaborators":60,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":11,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT","EXPERIMENTAL",null,[13],"Radiation: SBRT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","* 60Gy in 3 fractions (20Gy\u002Ffraction) over 14 days\n* 60Gy in 5 fractions (12Gy\u002Ffraction) over 18 days if organ at risk constraints cannot be met with fractionation above",[9],[20],"Stereotactic Body Radiation Therapy",[22],{"name":23,"affiliation":24,"role":25},"Andre TC Chen, MD, PhD","Instituto do Cancer do Estado de Sao Paulo","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":11,"email":30},"CONTACT","55-11- 3893-4540","andre.chen@hc.fm.usp.br",{"name":32,"role":28,"phone":33,"phoneExt":11,"email":34},"Karina Moutinho, MD","55-11-3893-4542","kamoutinho@gmail.com",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Instituto do Cancer do Estado de São Paulo","RECRUITING","São Paulo","01246-000","Brazil","BR",{"type":44,"coordinates":45},"Point",[46,47],-46.63611,-23.5475,{"lat":47,"lon":46},[50,53,55],{"name":51,"role":28,"phone":52,"phoneExt":11,"email":30},"Andre TC Chen, MD","55-11-3893-4540",{"name":32,"role":54,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"name":56,"role":54,"phone":11,"phoneExt":11,"email":11},"Rachel Riechelman, MD, PhD",{"type":25,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Andre Tsin Chih Chen","MD, PhD",[61],{"name":37,"class":6},"100223376","phase-2-stereotactic-body-radiation-therapy-sbrt-for-unresectable-liver-metastases-100223376",false,"NCT02185443","Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases","Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors","Inclusion Criteria:\n\n* Karnofsky Performance Scale (KPS) equal or greater than 70\n* 1 to 4 liver metastases with an individual maximum diameter of up to 5 cm\n* Lesions considered unresectable or patients considered unfit for surgery\n* Histology of the primary tumor: colorectal adenocarcinoma, carcinoma of the anal canal or gastrointestinal neuroendocrine tumors.\n* Absence of evidence of extra-hepatic disease or extra-hepatic disease to be treated with curative intent.\n* Minimum interval of 2 weeks between systemic chemotherapy and SBRT.\n* Adequate bone marrow function defined as:\n* absolute neutrophils count \\> 1,800 cells \u002F mm 3\n* platelets \\> 100,000 cells \u002F mm 3\n* hemoglobin \\> 8.0 g \u002F dl ( transfusion or other intervention accepted)\n\nExclusion Criteria:\n\n* Concomitant chemotherapy\n* Prior radiotherapy to the upper abdomen\n* Pregnancy\n* Underlying Cirrhosis\n* Active hepatitis or clinically significant liver failure\n* Prior invasive neoplasm except for non-melanoma skin cancer, or unless more than five years without evidence of disease\n* Severe Comorbidity\n* Current anticoagulant treatment","ALL","18 Years",{"count":72,"type":73},43,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent.\n\nTherefore, SBRT is being considered as a potentially curative procedure.",[79,80,81,82],"Liver Metastases","Colorectal Cancer","Anal Canal Cancer","Gastrointestinal Neuroendocrine Tumors",[9,84,85,86,87,88],"radiation","Neoplasm Metastasis","Colorectal Neoplasms","Anal Canal","Neuroendocrine Tumors","2024-12-04",{"date":91,"type":92},"2024-12-09","ACTUAL",{"date":94,"type":11},"2014-05",{"date":96,"type":73},"2026-12",{"name":5,"class":6},1]